Skip to main navigation

Skip to footer

For Individuals & Families:

For Individuals & Families For Individuals & Families

Shop for Plans

Member Guide Member Guide

Find a Doctor Find a Doctor

Natalizumab Injection

(na ta liz' you mab)

IMPORTANT WARNING:

Brand Name(s): Tyruko^® (natalizumab-sztn), Tysabri^®

IMPORTANT WARNING:

Receiving natalizumab injection products may increase the risk that you will develop progressive multifocal leukoencephalopathy (PML; a rare infection of the brain that cannot be treated, prevented, or cured and that usually causes death or severe disability). The chance that you will develop PML during your treatment with natalizumab products is higher if you have one or more of the following risk factors.

A blood test shows that you have been exposed to John Cunningham virus (JCV; a virus that many people are exposed to during childhood that usually causes no symptoms but may cause PML in people with weakened immune systems).
You have received many doses of natalizumab products, especially if you have received treatment for longer than 2 years.
You have ever been treated with certain medications that weaken the immune system.

Your doctor will probably order a blood test before or during your treatment with a natalizumab injection product to see if you have been exposed to JCV. If the test shows that you have been exposed to JCV, you and your doctor may decide that you should not receive a natalizumab injection product, especially if you also have one or both of the other risk factors listed above. If the test does not show that you have been exposed to JCV, your doctor may repeat the test from time to time during your treatment with natalizumab injection products. You should not be tested if you have had a plasma exchange (treatment in which the liquid part of the blood is removed from the body and replaced with other fluids) during the past 2 weeks because test results will not be accurate.

There are other factors that may also increase the risk that you will develop PML. Tell your doctor if you have or have ever had PML, an organ transplant, or another condition that affects your immune system such as human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS), leukemia (cancer that causes too many blood cells to be produced and released into the bloodstream), or lymphoma (cancer that develops in the cells of the immune system). Also tell your doctor if you are taking or if you have ever taken any other medications that affect the immune system. Your doctor may tell you that you should not receive natalizumab injection.

Because of the risks with this medication, natalizumab injection products are available only through a special restricted distribution program. Programs have been set up by the manufacturers of natalizumab injection products to be sure that people do not use natalizumab injection products without the necessary monitoring; these are called the TOUCH and TYRUKO REMS programs. You can only receive natalizumab injection products if you are registered with the TOUCH or TYRUKO program, if a natalizumab product is prescribed for you by a doctor who is registered with one of these programs, and if you receive the medication at an infusion center that is registered with one of these programs. Your doctor will give you more information about the program, will have you sign an enrollment form, and will answer any questions you have about the program and your treatment with natalizumab injection products.

Your doctor or nurse will give you a copy of the manufacturer's patient information sheet (Medication Guide) before you begin treatment with a natalizumab injection product and before you receive each infusion. Read this information very carefully each time you receive it and ask your doctor or nurse if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htmhttp://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer's website to obtain the Medication Guide.

Your doctor will need to see you every 3 months at the beginning of your treatment, then every 6 months during your treatment to decide whether you should continue using natalizumab products, and then at least 6 months after treatment is stopped. You will also need to answer some questions before you receive each infusion to be sure that natalizumab products is still right for you and other questions after treatment is stopped.

Call your doctor immediately if you develop any new or worsening medical problems during your treatment, and for 6 months after your final dose. Be especially sure to call your doctor if you experience any of the following symptoms: weakness on one side of the body that worsens over time; clumsiness of the arms or legs; changes in your thinking, memory, walking, balance, eyesight, or strength that last several days; confusion; or personality changes.

If your treatment with a natalizumab injection product is stopped because you have PML, you may develop another condition called immune reconstitution inflammatory syndrome (IRIS; swelling and worsening of symptoms that may occur as the immune system begins to work again after certain medications that affect it are started or stopped), especially if you receive a treatment to remove natalizumab products from your blood more quickly. Your doctor will watch you carefully for signs of IRIS and will treat these symptoms if they occur.

Tell all the doctors who treat you that you are receiving a natalizumab injection product.

Talk to your doctor about the risks of receiving a natalizumab injection product.

IMPORTANT NOTICE:

Natalizumab injection and natalizumab-sztn injection are biologic medications (medications made from living organisms). Biosimilar natalizumab-sztn injection is highly similar to natalizumab injection and work the same way as natalizumab injection in the body. Therefore, the term natalizumab injection products will be used to represent these medications in this discussion.

WHY is this medicine prescribed?

Natalizumab injection products are used to prevent episodes of symptoms and slow the worsening of disability in adults who have relapsing forms of multiple sclerosis (MS; a disease in which the nerves do not function properly and people may experience weakness, numbness, loss of muscle coordination, and problems with vision, speech, and bladder control), including:

clinically isolated syndrome (CIS; first nerve symptom episode that lasts at least 24 hours),
relapsing-remitting disease (course of disease where symptoms flare up from time to time),
active secondary progressive disease (later stage of disease with continuous worsening of symptoms.)

Natalizumab injection products are also used to treat and prevent episodes of symptoms in adults who have Crohn's disease (a condition in which the body attacks the lining of the digestive tract, causing pain, diarrhea, weight loss, and fever) who have not been helped by other medications or who cannot take other medications. Natalizumab is in a class of medications called monoclonal antibodies. It works by stopping certain cells of the immune system from reaching the brain and spinal cord or digestive tract and causing damage.

Information about Natalizumab Injection

Are there OTHER USES for this medicine?

HOW should this medicine be used?

Natalizumab injection products come as a concentrated solution (liquid) to be diluted and injected slowly into a vein by a doctor or nurse. It is usually given once every 4 weeks in a registered infusion center. It will take about 1 hour for you to receive your entire dose of a natalizumab injection product.

Natalizumab injection products may cause serious allergic reactions that are most likely to happen within 2 hours after the beginning of an infusion but may happen at any time during your treatment. You will have to stay at the infusion center for 1 hour after your infusion is finished for at least the first 12 infusions. A doctor or nurse will monitor you during this time to see if you are having a serious reaction to the medication. Tell your doctor or nurse if you experience any unusual symptoms such as hives, rash, itching, difficulty swallowing or breathing, wheezing, fever, dizziness, chest pain, flushing, nausea, or chills, especially if they occur within 2 hours after the start of your infusion.

If you are receiving a natalizumab injection product to treat Crohn's disease, your symptoms should improve during the first few months of your treatment. Tell your doctor if your symptoms have not improved after 12 weeks of treatment. Your doctor may stop treating you with natalizumab injection products.

Natalizumab injection products may help control your symptoms but will not cure your condition. Keep all appointments to receive a natalizumab injection product even if you feel well.

What SPECIAL PRECAUTIONS should I follow?

Before receiving a natalizumab injection product,

tell your doctor and pharmacist if you are allergic to natalizumab, any other medications, or any of the ingredients in natalizumab injection products. Ask your doctor or pharmacist for a list of the ingredients.
tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking. Be sure to mention the medications listed in the IMPORTANT WARNING section. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
tell your doctor if you have ever received natalizumab injection products before and if you have or have ever had any of the conditions listed in the IMPORTANT WARNING section. Before you receive each infusion of a natalizumab product, tell your doctor if you have a fever or any type of infection, including infections that last for a long time such as shingles (a rash that may occur from time to time in people who have had chickenpox in the past).
tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. If you become pregnant while receiving a natalizumab injection product, call your doctor.
If you received a natalizumab injection product while you were pregnant and have given birth, tell your baby's doctor that you received a natalizumab injection product. Natalizumab injection products may cause your baby to have low platelet (a type of blood cell) and red blood cell counts.
do not have any vaccinations without talking to your doctor.

What SPECIAL DIETARY instructions should I follow?

What should I do IF I FORGET to take a dose?

What SIDE EFFECTS can this medicine cause?

Natalizumab injection products may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

headache
extreme tiredness
drowsiness
joint pain or swelling
pain in arms or legs
back pain
swelling of the arms, hands, feet, ankles, or lower legs
muscle cramps
stomach pain
diarrhea
heartburn
constipation
gas
weight gain or loss
depression
night sweats
painful, irregular, or missed menstruation (period)
swelling, redness, burning, or itching of the vagina
white vaginal discharge
difficulty controlling urination
tooth pain
mouth sores
rash
dry skin
itching

Some side effects can be serious. If you experience any of the following symptoms or those mentioned in the HOW or IMPORTANT WARNING section, call your doctor immediately or get emergency medical treatment:

sore throat, fever, cough, chills, flu like symptoms, stomach cramps, diarrhea, frequent or painful urination, sudden need to urinate right away, or other signs of infection
yellowing of the skin or eyes, nausea, vomiting, extreme tiredness, loss of appetite, dark urine, right upper abdominal pain
sudden fever, severe headache, and confusion
vision changes, eye redness, or pain
unusual bleeding or bruising
small, round, red or purple-colored spots on the skin
heavy menstrual bleeding

Natalizumab injection products may cause other side effects. Call your doctor if you have any unusual problems while receiving this medication.

If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatchhttp://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

What should I do in case of OVERDOSE?

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/helphttps://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

What OTHER INFORMATION should I know?

Keep all appointments with your doctor and the laboratory. Your doctor may order certain lab tests to check your body's response to natalizumab injection products.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.

The American Society of Health-System Pharmacists, Inc. represents that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. makes no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS^® Patient Medication Information™. © Copyright, 2024. The American Society of Health-System Pharmacists^®, 4500 East-West Highway, Suite 900, Bethesda, Maryland. All Rights Reserved. Duplication for commercial use must be authorized by ASHP.

Selected Revisions: January 15, 2024.

This information does not replace the advice of a doctor. Ignite Healthwise, LLC, disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of UseTerms of Use. Learn how we develop our contenthow we develop our content.

Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Ignite Healthwise, LLC.

Page Footer

I want to...

Audiences

Secure Member Sites

The Cigna Group Information

Disclaimer

Individual and family medical and dental insurance plans are insured by Cigna Health and Life Insurance Company (CHLIC), Cigna HealthCare of Arizona, Inc., Cigna HealthCare of Illinois, Inc., Cigna HealthCare of Georgia, Inc., Cigna HealthCare of North Carolina, Inc., Cigna HealthCare of South Carolina, Inc., and Cigna HealthCare of Texas, Inc. Group health insurance and health benefit plans are insured or administered by CHLIC, Connecticut General Life Insurance Company (CGLIC), or their affiliates (see a listing of the legal entities a listing of the legal entities that insure or administer group HMO, dental HMO, and other products or services in your state). Accidental Injury, Critical Illness, and Hospital Care plans or insurance policies are distributed exclusively by or through operating subsidiaries of Cigna Corporation, are administered by Cigna Health and Life Insurance Company, and are insured by either (i) Cigna Health and Life Insurance Company (Bloomfield, CT); (ii) Life Insurance Company of North America (“LINA”) (Philadelphia, PA); or (iii) New York Life Group Insurance Company of NY (“NYLGICNY”) (New York, NY), formerly known as Cigna Life Insurance Company of New York. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. LINA and NYLGICNY are not affiliates of Cigna.

All insurance policies and group benefit plans contain exclusions and limitations. For availability, costs and complete details of coverage, contact a licensed agent or Cigna sales representative. This website is not intended for residents of New Mexico.

Selecting these links will take you away from Cigna.com to another website, which may be a non-Cigna website. Cigna may not control the content or links of non-Cigna websites. Details Details